Partnering Philosophy
One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances and a flexible and pragmatic approach to licensing and acquisitions. These are fundamental to the company’s continued growth and success.
Our strategy is to develop our business by licensing and acquiring products that we are able to directly market in the US or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma.
As a partner, Mayne Pharma offers:
- An established sales and marketing capability to bring new specialty brands and generic products into the US and Australian markets
- A management team and corporate culture committed to partnering
- A proven product development, manufacturing, quality, regulatory and supply chain logistics capability
- A flexible and creative approach to collaborations
- The ability to respond rapidly to opportunities
- A track record of successful partnering (some of our current partners include Pfizer, Boryung, ISDIN, Galderma, Corium, Douglas, Mithra, Formulytica and Teva)
The role of our Corporate and Business Development Department is to build strong, mutually beneficial relationships. The team’s role involves:
- Overseeing the selection and review of in-licensing and acquisition opportunities
- Managing the out-licensing process
- Actively pursuing strategic alliances
In-Licensing
Mayne Pharma is seeking to rapidly expand its product portfolio in the US and Australia. Our business development activities are focused on prescription branded and generic products that are in late-stage development, currently approved and commercialized outside the US or Australia, or approved in the US or Australia but falling outside the license holder’s business focus. We will consider in-licensing, acquisition, co-promotion, revenue-sharing, and other partnering opportunities.
Therapeutic categories of primary interest for proprietary products include dermatology, pain management, infectious disease, women’s health and urology, although we will consider other opportunities outside of these areas.
For partnering enquiries please contact us.
Out-Licensing
Mayne Pharma is working to expand its global strategic marketing partnerships for products developed-in house. Mayne Pharma products typically incorporate proprietary drug delivery technology offering a therapeutic benefit.
Refer to Specialty Technologies for further information about Mayne Pharma’s oral drug delivery technology experience which includes SUBA® bioavailability enhancement, taste masking and customised controlled-release drug delivery.
Explore our full line of branded and generic products
For partnering enquiries please contact us.